Forty Seven Raises $75m For Potential 'Universal' CD47 Cancer Therapy

Forty Seven Inc. has $75m in Series A venture capital and something else that's pretty novel for a startup biotechnology company: an immuno-oncology development program that's already in the clinic with data expected later this year.